56 completed, 18 active not recruiting, 14 terminated, 12 recruiting. 62 Phase 2, 30 Phase 3, 9 Phase 1, 5 Phase 4, 4 Not applicable.
Follow Degarelix: new trials by email Literature Review of Degarelix trials Research Report on Degarelix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer Androgen Deprivation Therapy (ADT), Radiotherapy - Prostate Cancer | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-08-06 | 2026-09-03 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer BMS-986165, Degarelix - Prostate Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2026-01-09 | 2026-10-05 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer ADT, Enzalutamide, Talazoparib - Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-06-03 | 2026-11-02 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer Darolutamide, Degarelix, Radiation Therapy - Prostate Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 208 | 2024-07-02 | 2024-01-24 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Cardiometabolic Consequences of the Loss of Ovarian Function Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch - Menopause, Estrogen Deficiency | Phase 4 | Recruiting | University of Colorado, Denver | 100 | 2024-06-01 | 2024-06-20 |
| A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer Copanlisib, Degarelix, Radical Prostatectomy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2024-01-11 | 2024-10-31 | |
| ETHAN - ET for Male BC Tamoxifen, Anastrozole, Degarelix - Male Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 2 | Recruiting | Jose Pablo Leone | 60 | 2023-10-11 | 2026-08-24 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Degarelix, Gemcitabine/Cisplatin - Urothelial Carcinoma Bladder, Androgen Receptor Positive | Phase 1 | Terminated | Brown University | 2 | 2023-10-02 | 2026-04-02 |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate - Metastatic Prostate Cancer, Non-metastatic Prostate Cancer | Phase 1 | Terminated | Praful Ravi, MB BCHir, MRCP | 9 | 2023-08-09 | 2026-10-15 |
| Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer Degarelix, MRI-guided transurethral ultrasound ablation (TULSA) - Localized Prostate Carcinoma, Castration-Naive Prostate Cancer | Phase 1 | Active not recruiting | Turku University Hospital | 15 | 2023-07-18 | 2026-10-13 |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland abiraterone, enzalutamide, docetaxel - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Pfizer | 1083 | 2023-02-13 | 2026-01-29 | |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel - Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2022-01-25 | 2025-12-04 |
| Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Degarelix, pTVG-AR, Nivolumab - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Wisconsin, Madison | 57 | 2021-12-16 | 2026-09-30 |
Showing 20 of 114. Sign in to see all of them.
Prostatic Neoplasms (93) · Prostatic Hyperplasia (2) · Urinary Bladder Neoplasms (2) · Breast Neoplasms, Male (1) · COVID-19 (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Cardiovascular Diseases (1) · Endometriosis (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Obesity (1)
Ferring Pharmaceuticals (37) · Memorial Sloan Kettering Cancer Center (6) · M.D. Anderson Cancer Center (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Astellas Pharma Inc (3) · NRG Oncology (3) · British Columbia Cancer Agency (2) · City of Hope Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mark Stein (2) · Mayo Clinic (2) · The University of Texas Health Science Center, Houston (2) · Turku University Hospital (2) · University Health Network, Toronto (2) · University of Colorado, Denver (2)
United States (63) · Canada (19) · Germany (16) · United Kingdom (12) · Finland (11) · Belgium (10) · France (9) · Netherlands (9) · Romania (9) · Russia (8) · Hungary (7) · Italy (6) · Czechia (5) · Denmark (4) · Mexico (4)
Jingsong Zhang, MD, PhD (2) · Mark N. Stein, MD (2) · Michael Zelefsky, MD (2) · Samuel Denmeade, MD (2) · Alejandro Berlin, MD (1) · Alvaro A. Martinez, MD, FACR (1) · Amado Zurita-Saavedra, MD (1) · Ana M. Aparicio, MD (1) · Arpit Rao, MD (1) · Arthur Hung (1) · Brian Chapin (1) · Chi Fai NG, MD (1)
PMID 34350976, PMID 18538469, PMID 18801505, PMID 19035858, PMID 21788033, PMID 22500884, PMID 23257248, PMID 23258223, PMID 27756786, PMID 29398594, PMID 29545772, PMID 29606109, PMID 29624800, PMID 30589600, PMID 31611635, PMID 34225789, PMID 34396210, PMID 34459214, PMID 35438754, PMID 35971857, PMID 36161511, PMID 37104748, PMID 37922910, PMID 38421243, PMID 38656229, PMID 41759531, PMID 41781018, PMID 42117295, PMID 42221687
2008 (5), U10CA180868 (3), P30CA015704 (2), 2014 (1), 2015 (1), 2016 (1), P30CA006973 (1), P30CA033572 (1), P50CA269011 (1), P50CA272390 (1), P50CA272391 (1), R01CA286127 (1), R01CA300454 (1), U10CA180820 (1), U10CA180821 (1)